Document 71DLvnMjNqaZZB02jRpbgB01B

To: Veenstra, Gauke GE SC-CHSE-GV <Gauke.E.Veenstra@OPC.shell.com> From: Clegg, Patsy M SCC-CHSE-PC </O=SHE LUOU=MSXSCC/CN=RE CI PI ENTS/CN=PH197432> Cc: Tsai, Shan SP SHLOIL-SPS <sptsai@SheII.Com>; De Jong, Geert G SI-HE/2 <Geert.G.deJong@Sl.shell.com>; Cagen, Stuart Z SCC <szcagen@SheII.Com>; Boogaard, Peter J SI-HE/2 <Peter.J.Boogaard@si.shell.com>; English, Timothy A SCC <taenglish@SheII.Com> Bcc: Received Date: 2002-02-1816:14:23 GMT Subject: RE: feasibility study Gauke, The aromatics business position is for Shell to support this study being done. We should be actively involved in reviewing the report. This study would be added to the growing body of information that supports our need to further our involvement in product stewardship activities as evidenced by our support of the Shanghai Health Study. I will leave technical comments to the technical experts addressed in your distribution list. Thank you for keeping us updated. Patsy Clegg Product Steward Shell Chemical LP One Shell Plaza, 91 0 Louisiana, Houston, TX 77002-4916 Tel: +1 713241 2521 Fax: 3325 Email: pmclegg@shellus.com Internet: http://www.shell.com/chemicals -----Original Message----From: Veenstra, Gauke GE SC-CHSE-GV Sent: Monday, February 18, 2002 3:06 AM To: Tsai, Shan SP SHLOIL-SPS; De Jong, Geert G SI-HE/2; Cagen, Stuart Z SCC; Boogaard, Peter J SI-HE/2 Cc: Clegg, Patsy M SCC-CHSE-PC Subject: FW: feasibility study Dear all, Just received this from Chris Money from Exxon Mobil. I will participate in the CEFIC APA existing chem. group which meets on the 20th of February; I suspect that this will be discussed, although I expect not in great detail and no decision will be taken during this meeting. Let me have any comments you would want to introduce at this [early] stage. Chris Money asked me not to distribute this outside Shell. Regards, Gauke Veenstra Toxicology Advisor Shell Chemicals Limited Shell Centre, London SE1 7NA, United Kingdom Tel: +442079343448 Fax: 7627 SH ELL-MCCLU RG-055322 Email: Gauke.E.Veenstra@OPC.SheILcom Internet: http://www.sheILcom -----Original Message----From: chris.money@exxonmobil.com [mailto:chris.money@exxonmobil.com] Sent: 18 February 200207:37 To: jau@cefic.be; Bo.Dmytrasz@concawe.be; Veenstra, Gauke GE SC-CHSE-GV; Ipottenger@dow.com; cgi@cefic.be; Jacqueline.BAKES@atofina.com Cc: jan. urbanus@concawe.be; roythorc@ bp. com Subject: feasibility study Dear All I have just received from Rob Schnatter the final draft of the EMBSI report on the feasibility of conducting a pooled analysis on the HW, IOL and IP cohorts. You will recall that APA originally sponsored this work, resulting in a mtg of the P.L's from the UK IP, IOL and Health Watch cohorts at EMSI last July. In terms of process therefore, I suggest that the APA Existing Chemicals group takes the responsibility for initially looking at the document and providing any comments (including those which CONCAWE may have). However, as the report is still at a draft stage, I think it would be sensible not to distribute this document widely. Once a final report is available, that will provide a better basis for wider discussions. Christian, can we plse add this to the agenda for the ECG mtg this Wednesday? Thanks Chris Money Industrial Hygiene Advisor - Europe Exxon Mobil Petroleum & Chemical Hermeslaan 2 B-1831 Machelen Belgium Tel: +32(0)2 722 4230 (Fax: x3802) Please note my Email has now changed to Chris.Money@ExxonMobiLcom ----- Forwarded by Chris Money/BeneluxlExxonMobil on 18/02/02 08:08 ----- A R Schnatter To: cc: 18/02/02 06:29 Chris Money/BeneluxlExxonMobil@xom Subject: feasibility study Chris - here is a final draft of the feasibility sudy i promised you. I know you need it for APA. Why don't you circulate it there, and I'll do all the other formalities later. Monday is a co. holiday -- I'll be at home - 908-359-2385 if you need me. Rob(See attached file: SH ELL-MCCLU RG-055323 enhancedanaI5Part1.doc) Rob Schnatter 908-730-11 01 Room LF-252 Exxon Mobil Biomedical Sciences, Inc. 1545 Route 22 East Annandale, NJ 08801-0971 SH ELL-MCCLU RG-055324